Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158)

Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Woelwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J (2024)


Publication Type: Journal article, Erratum

Publication year: 2024

Journal

Book Volume: 213

Article Number: 115074

DOI: 10.1016/j.ejca.2024.115074

Abstract

The authors removed the study acronym ‘RECAP’ throughout the article. The authors would like to add the following to acknowledgement section of the publication.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Kron, A., Scheffler, M., Wiesweg, M., Hummel, H.D., Kulhavy, J., Gatteloehner, S.,... Wolf, J. (2024). Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158). European Journal of Cancer, 213. https://doi.org/10.1016/j.ejca.2024.115074

MLA:

Kron, Anna, et al. "Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158)." European Journal of Cancer 213 (2024).

BibTeX: Download